Credit Suisse Ag Otonomy, Inc. Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$3.7 - $4.75 $39,919 - $51,247	-10,789 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$4.05 - $6.1 $43,695 - $65,812	10,789 New	10,789 $44,000
Q4 2017 Feb 14, 2018	SELL	$2.8 - $5.55 $89,608 - $177,616	-32,003 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$3.2 - $20.8 $33,964 - $220,771	10,614 Added 49.62%	32,003 $104,000
Q2 2017 Aug 14, 2017	BUY	N/A	21,389	21,389 $403,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.